Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.
Sign Up to like & getrecommendations! Published in 2019 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000795
Abstract: Four ovarian cancer patients with severe plantar palmar erythrodysesthesia or mucositis precluding further therapy from pegylated liposomal doxorubicin on the standard every 4 week schedule were able to be treated on every 2-week schedule without… read more here.
Keywords: liposomal doxorubicin; skin mucosal; pegylated liposomal; every week ... See more keywords